uploads///Graph Part

XBI Moving Averages Are on the Rise

By

Nov. 20 2020, Updated 5:08 p.m. ET

XBI moving averages

For the week ended September 11, 2015, the SPDR S&P Biotechnology ETF (XBI) saw a big jump in the number of stocks trading above the 20-day moving average. Within XBI, 75.73% of the stocks traded above the 20-day moving average, 33.98% traded above the 50-day moving average, and 39.81% traded above the 100-day moving average.

Compared to the previous week ended September 4, the percentage of stocks trading above 20-day, 50-day, and 100-day moving averages was 27.08%, 15.63%, and 20.83%, respectively.

Article continues below advertisement

The above graph reflects the trend of percentage of stocks trading above the various moving averages. In number terms, 78 stocks were trading above the 20-day, 35 stocks were trading above the 50-day, and 41 stocks were trading above the 100-day moving averages for the week ended September 11. For the previous week ended September 4, the numbers were 26, 15, and 20, respectively.

Seattle Genetics and Puma Biotechnology move back to 20-day moving averages

Seattle Genetics (SGEN) gained 14.56% for the week ended September 11, 2015. The stock closed at $45.01 and moved back to 20-day, 50-day, and 100-day moving averages.

According to the press release, SGEN announced that the company and its collaborator, Takeda Pharmaceutical, completed patient enrollment in the Phase 3 Alcanza clinical trial. The trial will evaluate Adcetris (brentuximab vedotin) in CD30-expressing cutaneous T-cell lymphoma (CTCL).

SGEN also announced the pricing of its public offering of common stock at $41 per share. SGEN has a weight of 0.91% in XBI.

Article continues below advertisement

Puma Biotechnology (PBYI) gained 14.08% for the week ended September 11. According to the press release, Puma announced that “a publication in the September 2015 issue of the Journal of the National Comprehensive Cancer Network describes that a patient with HER2 non-amplified (HER2-negative) metastatic breast cancer who also had an HER2 activating mutation was successfully treated with PB272 (neratinib).”

PBYI closed at $103.28 and traded above 20-day and 50-day moving averages. PBYI has a weight of 0.63% in XBI.

Intrexon (XON) rose 8.91% that same week and bounced back from its recent low of $41.21. The stock closed at $44.88 on September 11, trading just above the 20-day moving average. According to the press release, XON was slated to participate in J.P. Morgan’s 6th Annual All Stars Conference in London on September 15–16.

Dyax (DYAX) gained 3.63% for the week ended September 11. The press release said DYAX would be participating in the Morgan Stanley Global Healthcare Conference held on September 16–18 in New York City. DYAX has a weight of 0.88% in XBI.

Advertisement

More From Market Realist